Treatment of Drug resistant Gram negative|ESCMID& IDSA|Learn with DrAkshatha|CRE|ESBL|AmpC|CRAB|CRPA

Sdílet
Vložit
  • čas přidán 24. 12. 2021

Komentáře • 15

  • @ccbowers
    @ccbowers Před 2 lety +1

    Another important limitation in interpreting Merino 2, and other studies that are evaluating potentially chromosomal ampC Induceable organisms, is that these studies often lump together organisms that should not be (because of now outdated understandings).
    For example, including serratia marcesens, providencia sp, and morganella morganii, organisms that are much less likely to have clinical relevant AmpC expression, along with Citrobacter freundii, enterobacter sp, and Klebs aerogenes, dilutes any differences that may be present in the latter group.

  • @02_ix-a_aashitaroy98
    @02_ix-a_aashitaroy98 Před 7 měsíci

    very nice lecture mam as usual, Mam pls take a lecture on ceftazidime avibactam and aztreonam synergy testing & how to interpret it.

  • @fjcoolej
    @fjcoolej Před 2 lety +1

    Great presentation madam 👍🏻👌🏻👌🏻In detail discussion of escmid would be awesome🙏

  • @kalpanathangavelu5665
    @kalpanathangavelu5665 Před 2 lety +1

    Very informative presentation mam. Great job👏👏

  • @drsomadey2850
    @drsomadey2850 Před 2 lety +1

    Very nice, informative, & simplified

  • @RajRaj-lb8fc
    @RajRaj-lb8fc Před 11 měsíci

    Hi Dr well done in delivering. Kindly describe more on the laboratory aspects. Clinician expect the laboratory to automatically report all 3 G cephalosporin RESISTANT if automated machines report ESBL. But I think this is against what CLSI is saying. CLSI now says report as it is with current breakpoints. I need clarification or a video tutorial on this if possible.

  • @abhishekgp7864
    @abhishekgp7864 Před 2 lety +1

    Keep up the good work 👏

  • @shanmugavadivoonatarajan3639

    Explicit presentation Dr.Akshata.

  • @dmidaiimsjdh8170
    @dmidaiimsjdh8170 Před 2 lety +1

    Good